Maxime Barakat
Overview
Explore the profile of Maxime Barakat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tardio V, Yin P, Camacho F, Barakat M, Tsoukas M
Diabetes Obes Metab
. 2025 Feb;
PMID: 39927409
Aims: Oral treatment extended-release naltrexone/bupropion (NB) leads to significant weight loss, but its effect on body composition remains unclear. We investigated changes in body composition with dual-energy x-ray absorptiometry after...
2.
Morsica G, Messina E, Bagaglio S, Galli L, Lolatto R, Sampaolo M, et al.
Microorganisms
. 2024 Jun;
12(6).
PMID: 38930529
The emergence of new SARS-CoV-2 variants can affect vaccine efficacy, laboratory diagnosis and the therapies already available, triggering interest in the search for antiviral agents for SARS-CoV-2 infections. Ribavirin (RBV)...
3.
Papp K, Prajapati V, Maari C, Legault M, Barakat M, Vender R
J Am Acad Dermatol
. 2024 Jan;
90(6):1254-1256.
PMID: 38290619
No abstract available.
4.
Lee-Baggley D, Fils-Aime N, Audet I, Barakat M
Clin Obes
. 2023 Oct;
14(1):e12624.
PMID: 37846529
In this study, we sought to analyse experiences in weight management among physicians working in the area of obesity and contrast these experiences with best practices. By understanding experiences of...
5.
Ribavirin aerosol in hospitalized adults with respiratory distress and COVID-19: An open-label trial
Poulakou G, Barakat M, Israel R, Bacci M
Clin Transl Sci
. 2022 Nov;
16(1):165-174.
PMID: 36326174
There is an unmet medical need for effective treatments for hospitalized patients with coronavirus disease 2019 (COVID-19). Ribavirin is a broad-spectrum antiviral with demonstrated in vitro activity against multiple viruses,...
6.
le Roux C, Fils-Aime N, Camacho F, Gould E, Barakat M
EClinicalMedicine
. 2022 Jun;
49:101436.
PMID: 35747175
Background: Extended-release (ER) naltrexone/bupropion (NB) was associated with greater weight loss than placebo in four randomized, 56-week trials. The association of NB with longer-term maintenance of weight loss remains unknown....
7.
Vender R, Turchin I, Lansang P, Prajapati V, Legault M, Barakat M, et al.
JAAD Int
. 2022 Jun;
8:60-63.
PMID: 35721301
No abstract available.
8.
Couroux P, Brkovic A, Vittitow J, Israel R, Pamidi C, Patel J, et al.
Clin Transl Sci
. 2022 Jun;
15(9):2159-2171.
PMID: 35677972
Ribavirin is an inosine monophosphate dehydrogenase inhibitor. Studies suggest ribavirin aerosol could be a safe and efficacious treatment option in the fight against coronaviruses. However, current treatment is long (12-18 ...
9.
Wharton S, Macklin D, Morin M, Blavignac J, Menzies S, Garofalo L, et al.
BMC Prim Care
. 2022 May;
23(1):101.
PMID: 35501830
Background: Obesity is a chronic problem in Canada and although the Canadian Medical Association recognizes obesity as a disease, health care professionals (HCPs) are not necessarily proactively managing it as...
10.
Ucakhan O, Tasindi E, Toker E, Ciftci F, Kurna S, Acar M, et al.
Ophthalmol Ther
. 2021 Oct;
10(4):973-974.
PMID: 34677791
No abstract available.